Use of glucagon‐like peptide‐1 receptor agonists and bone fractures: A meta‐analysis of randomized clinical trials (胰高血糖素样肽‐1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)

Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of bone fractures independent of the use of antidiabetic medications. Furthermore, antidiabetic medications could directly affect bone metabolism. Recently, the use of dipeptidyl peptidase-4 inhibitors has been associated with a lower rate of bone fracture. The aim of the present meta-analysis was to assess whether patients with T2DM treated with glucagon-like peptide-1 receptor agonists (GLP-1Ra) present a lower incidence of bone fracture compared with patients using other antidiabetic drugs.